Roche Looks for New Spin on Xenical

May 2000
Pharmaceutical Executive;May2000, Vol. 20 Issue 5, p154
Trade Publication
Announces the search of Hoffman-La Roche for an advertising agency to promote its antiobesity drug Xenical. Revenues generated by sales of the drug for the first quarter of 2000; Advertising expenditures of the company for the drug; Media buys that the company initiated.


Related Articles

  • Fighting fat.  // Drug Topics;6/2/97, Vol. 141 Issue 11, p30 

    Reports on the US Food and Drug Administration's approval of Hoffmann-La Roche's anti-obesity drug Xenical.

  • Roche resubmits Xenical NDA in face of phen-fen legal action.  // Medical Marketing & Media;Dec97, Vol. 32 Issue 12, p24 

    Reports that Hoffmann-La Roche has resubmitted its new drug application for the anti-obesity drug Xenical or orlistat at the US Food and Drug Administration. Mechanism of action of Xenical; Recall of the anti-obesity drugs Pondimin and Redux.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

  • Novel drug promotes weight loss, reduces obesity-related risks. Portyansky, Elena // Drug Topics;5/17/99, Vol. 143 Issue 9, p27 

    Focuses on Xenical, an antiobesity drug from Hoffmann-La Roche. Weight-loss benefits of orlistat; Side-effects of the drug; Information on minimizing the drug's side-effects. INSET: Tips to Remember.

  • Fat-Blocking Drug Can Help Fight Obesity.  // FDA Consumer;Jul/Aug99, Vol. 33 Issue 4, p2 

    Reports on the anti-obesity Xenical made by Roche Laboratories Inc. that works by blocking the body's absorption of fat. Results of the long-term clinical trials on the lipase inhibitor; Diet of a patient during treatment; Common side effects of the drug.

  • Roche picks Lowe shops for new anti-obesity drug. Gleason, Mark; Wilke, Michael // Advertising Age;10/14/1996, Vol. 67 Issue 42, p60 

    Tells that Roche Laboratories chose a team of advertising agencies to handle the launch of a new prescription anti-obesity treatment. Roche's orlistat, to be marketed under the name Xenical; Aggressive marketing plan; Pending approval from the US Food & Drug Administration; Comparision to other...

  • WOLFE: STRICTER CONTROL OF DTC NEEDED. Dickinson, James G. // Medical Marketing & Media;Apr2002, Vol. 37 Issue 4, p34 

    Reports developments related to direct-to-consumer advertising of drugs in the U.S. as of April 2002. Increase in the direct-to-consumer promotions; Failure of Hoffmann-LaRoche Inc. to include statements of side effects on the Xeloda advertisement; Preference of drug companies to use network...

  • Honesty is the Best Policy. Hallahan, Mary; Mordock, Jeff // Pharmaceutical Executive;Nov99, Vol. 19 Issue 11, p87 

    Provides information on the direct-to-consumer advertising for Hoffmann-La Roche's diet drug, Xenical. Budget for the campaign; Analysis of Xenical advertisements; Goal of the campaign.

  • Orlistat patients offered weight-loss support guidelines. Beyzarov, Elena Portyansky // Drug Topics;5/1/2000, Vol. 144 Issue 9, p32 

    Focuses on a health program from Hoffmann-La Roche company which helps patients taking the diet drug Xenical set realistic expectations on weight loss. Paraphernalia included in the starter kit; Information on the obesity management guidelines.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics